An Open Label Study to Evaluate the Safety and Effect on Disease Activity of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-Biologic DMARDs Who Have an Inadequate Response to Current Non-Biologic DMARDs.
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 15 Jun 2010 Planned end date changed from 1 Mar 2010 to 1 Aug 2010 as reported by ClinicalTrials.gov.
- 26 May 2010 Status changed from recruiting to active, no longer recruiting as reported by Roche record.